<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:atom="http://www.w3.org/2005/Atom"
xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
>
<channel>
	<title>ThaiPR.NET</title>
	<atom:link href="https://www.thaipr.net/location/cincinnati/feed" rel="self" type="application/rss+xml" />
	<link>https://www.thaipr.net/location/cincinnati</link>
	<description>Press Release Distribution Center of Thailand</description>
	<lastBuildDate>Wed, 22 Apr 2026 17:18:21 +0700</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.1.1</generator>
	<item>
		<title><![CDATA[Avo Automation Announces Continued Momentum Through New Leadership Appointments, Expanded Coverage and Customer Benefits]]></title>
		<link>https://www.thaipr.net/en/it_en/3217484</link>
		<dc:creator><![CDATA[thaipr.net]]></dc:creator>
		<pubDate>Tue, 26 Jul 2022 16:45:00 +0700</pubDate>
				<category>it_en</category>
		<guid isPermaLink="false">https://www.thaipr.net/en/it_en/3217484</guid>

					<description><![CDATA[<p>Manish Jha, Sachin Chandavarkar and Shankaranarayana Adiga appointed to leadership roles Avo Automation, the leading solution for automated software testing and test data management, today announced its continued momentum demonstrated by new leadership appointments, expanded availability and new customer benefits. Avo Automation has appointed Manish Jha as Senior Director, Product Head, Sachin Chandavarkar as Senior Director – [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.thaipr.net/en/it_en/3217484">Avo Automation Announces Continued Momentum Through New Leadership Appointments, Expanded Coverage and Customer Benefits</a> appeared first on <a rel="nofollow" href="https://www.thaipr.net">ThaiPR.NET</a>.</p>
]]></description>
									</item>
		<item>
		<title><![CDATA[Standard Textile and Kucukcalik Announce Joint Venture to Accelerate Growth in Markets]]></title>
		<link>https://www.thaipr.net/en/general_en/3068970</link>
		<dc:creator><![CDATA[thaipr.net]]></dc:creator>
		<pubDate>Fri, 25 Jun 2021 08:00:29 +0700</pubDate>
				<category>general_en</category>
		<guid isPermaLink="false">https://www.thaipr.net/en/general_en/3068970</guid>

					<description><![CDATA[<p>Standard Textile Co., Inc. and Kucukcalik today announce they have entered into a joint venture agreement. The joint venture agreement brings together the specialized expertise and knowledge of two leading textile manufacturing companies to expand their product portfolio and accelerate growth in the healthcare, hospitality, and consumer markets.  Kucukcalik is a premier global textile manufacturing [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.thaipr.net/en/general_en/3068970">Standard Textile and Kucukcalik Announce Joint Venture to Accelerate Growth in Markets</a> appeared first on <a rel="nofollow" href="https://www.thaipr.net">ThaiPR.NET</a>.</p>
]]></description>
									</item>
		<item>
		<title><![CDATA[Airway Therapeutics Announces FDA Acceptance of IND for AT-100&#8217;s Second Indication in Severe COVID-19 Patients]]></title>
		<link>https://www.thaipr.net/en/general_en/3046548</link>
		<dc:creator><![CDATA[thaipr.net]]></dc:creator>
		<pubDate>Mon, 12 Apr 2021 15:15:00 +0700</pubDate>
				<category>general_en</category>
		<guid isPermaLink="false">https://www.thaipr.net/en/general_en/3046548</guid>

					<description><![CDATA[<p>Initiating Phase 1b clinical trial with initial results expected 3Q2021 Potential for novel therapeutic AT-100 to inhibit viral replication, promote viral elimination and reduction of lung injury, inflammation, and secondary infections in severe COVID-19 patients Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.thaipr.net/en/general_en/3046548">Airway Therapeutics Announces FDA Acceptance of IND for AT-100&#8217;s Second Indication in Severe COVID-19 Patients</a> appeared first on <a rel="nofollow" href="https://www.thaipr.net">ThaiPR.NET</a>.</p>
]]></description>
									</item>
		<item>
		<title><![CDATA[Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)]]></title>
		<link>https://www.thaipr.net/en/health_en/3042196</link>
		<dc:creator><![CDATA[thaipr.net]]></dc:creator>
		<pubDate>Fri, 26 Mar 2021 15:30:14 +0700</pubDate>
				<category>health_en</category>
		<guid isPermaLink="false">https://www.thaipr.net/en/health_en/3042196</guid>

					<description><![CDATA[<p>Initiating Phase 1b randomized clinical trial with initial results expected in late 2021 Potential for novel, preventive AT-100 to reduce incidence and severity of serious respiratory disease BPD, improving outcomes and survival in very preterm infants Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.thaipr.net/en/health_en/3042196">Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)</a> appeared first on <a rel="nofollow" href="https://www.thaipr.net">ThaiPR.NET</a>.</p>
]]></description>
									</item>
		<item>
		<title><![CDATA[Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round]]></title>
		<link>https://www.thaipr.net/en/general_en/3042012</link>
		<dc:creator><![CDATA[thaipr.net]]></dc:creator>
		<pubDate>Fri, 26 Mar 2021 09:30:29 +0700</pubDate>
				<category>general_en</category>
		<guid isPermaLink="false">https://www.thaipr.net/en/general_en/3042012</guid>

					<description><![CDATA[<p>Amplicore Inc., an early-stage biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases, has successfully closed its Series Seed round of funding at $4 million. Investments were led by Photon Fund, with participation from Industrial Technology Investment Corporation, Berkeley Catalyst Fund, and SVE Capital. &#8220;We are very pleased to have [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.thaipr.net/en/general_en/3042012">Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round</a> appeared first on <a rel="nofollow" href="https://www.thaipr.net">ThaiPR.NET</a>.</p>
]]></description>
									</item>
	</channel>
</rss>
